Profusa Received Certification and Shares Surged
The company obtained ISO 13485 certification as it pursues regulatory approval for its biosensor technology.
Updated on Sept. 24, 2026 in Healthcare
Live Poll
Do you trust the long-term potential of micro-cap stocks following positive regulatory news?
Profusa secured a positive quality management system certification from GMED, marking a significant step toward achieving CE marking under European Union Medical Device Regulation. Following the announcement, the company saw its share price jump by 50.70 percent.
Why it matters
The certification validates the quality management system for the Lumee Oxygen Platform, a biosensor technology designed to monitor tissue oxygen levels. This regulatory progress is a critical precursor for the company to bring its diagnostic platform to the European market.
Profusa stock closed at $3.08, reflecting a 50.70% increase compared to its 52-week low of $1.58. The company is currently working to finalize conformity assessments for the European Union market.
The players
Profusa
This biotechnology company develops tissue-integrated biosensor technology for monitoring physiological data.
GMED
This organization serves as a notified body for medical devices within the European Union regulatory framework.
G3 Vision Labs
This firm is a diagnostics company that Profusa entered into an option agreement to acquire.
The details
Profusa is utilizing GMED, a notified body, to navigate the complexities of European Union Medical Device Regulation. The firm also holds an option agreement to acquire G3 Vision Labs, which recorded approximately $111 million in sales during 2025.
Timeline
In 2025, G3 Vision Labs generated an estimated $111 million in sales.
Profusa signed an option agreement to acquire G3 Vision Labs in July 2026.
On September 24, 2026, Profusa received the GMED certification and saw its stock price climb.
Market Landscape
This certification effort is part of a broader push to standardize diagnostic technologies under the European Union Medical Device Regulation. Successfully clearing these regulatory hurdles positions Profusa to compete as a significant player in the international medical diagnostics sector.
The regulatory progress suggests that the Lumee Oxygen Platform may soon reach new clinical settings, potentially improving how healthcare providers monitor tissue oxygen. Retail investors should note that the company's valuation has seen significant volatility following these corporate updates.
The takeaway
Obtaining standardized quality certification is a vital milestone for biotech companies attempting to expand into strictly regulated international markets. Investors often monitor these regulatory updates as key indicators of a company's ability to successfully commercialize new diagnostic technology.
Further reading
Learn more about the latest developments in the Healthcare sector.
Source note: This article includes information reported by Benzinga.
Live Poll
Do you trust the long-term potential of micro-cap stocks following positive regulatory news?
